Timothy Baxter v. Robert Kennedy, Jr.

136 F.4th 70
Court of Appeals for the Fourth Circuit·Decided April 29, 2025·No. 24-1203·Published

Opinion

PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 24-1203

DR. TIMOTHY BAXTER, Plaintiff – Appellant,

v.

ROBERT F. KENNEDY, JR., in his official capacity as Secretary, Department of Health and Human Services; JULIET T. HODGKINS, in her official capacity as Acting Inspector General, Department of Health and Human Services,

Defendants – Appellees.

Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. Roderick Charles Young, District Judge. (3:23-cv-00092-RCY)

Argued: October 29, 2024 Decided: April 29, 2025

Before AGEE, RICHARDSON, and BERNER, Circuit Judges.

Affirmed by published opinion. Judge Richardson wrote the opinion, in which Judge Agee and Judge Berner joined.

ARGUED: Thomas M. Johnson, Jr., WILEY REIN LLP, Washington, D.C., for Appellant. Rebecca Sara Levenson, OFFICE OF THE UNITED STATES ATTORNEY, Alexandria, Virginia, for Appellees. ON BRIEF: Brandon J. Moss, Jeremy J. Broggi, Michael J. Showalter, William Turner, WILEY REIN LLP, Washington, D.C., for Appellant. Maddie J. Bainer, Senior Counsel, Office of Counsel to the Inspector General, UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, Washington, D.C.; Jessica D. Aber, United States Attorney, Jonathan T. Lucier, Assistant

United States Attorney, OFFICE OF THE UNITED STATES ATTORNEY, Richmond, Virginia, for Appellees.

RICHARDSON, Circuit Judge:

This appeal turns on a little-known provision of the Social Security Act, 42 U.S.C.

§ 1320a-7(a). That subsection adds an additional consequence to certain healthcare-related crimes by commanding the Health Secretary to ban persons who commit them from working with federal healthcare programs. Among the covered offenses are those “related to the delivery of an item or service . . . under any State health care program.” 42 U.S.C. § 1320a-7(a)(1).

Dr. Timothy Baxter faces the business end of such a ban. While working for a pharmaceutical company called Indivior, Baxter distributed misinformation to Massachusetts’s Medicaid program about the safety of new opioid drugs. That is a federal offense. And when federal prosecutors caught up with him, Baxter pleaded guilty. On the back of that prior offense, the Secretary subsequently banned him from working with federal healthcare programs for five years.

Now, Baxter challenges his exclusion. He floats an interpretation of the additional-

consequence statute’s subsection (a) on which that subsection mandates exclusion only if his crime categorically relates to the delivery of an item or service under a state healthcare program. No federal court of appeals has adopted this argument. We will not be the first. The text and context of the mandatory-exclusion subsection make clear that it looks to what the individual actually did, not to offenses in the abstract. It thus requires only that the actual conduct be “related to” the specific acts listed in the statute. Baxter’s actual conduct satisfies that requirement and thereby triggered mandatory exclusion.

I. Background A. At Indivior, Baxter Misbrands Opioids Baxter used to be the Global Medical Director at Indivior, a pharmaceutical company that produces the opioid drugs Suboxone and Subutex. 1 Suboxone and Subutex are designed to help wean those who struggle with addiction off other, more dangerous opioids. Both drugs have saved lives. But they aren’t risk-free. Like the drugs they seek to replace, these drugs still contain opioids. So one of the drugs—Suboxone—contains a second substance that induces withdrawal symptoms when insufflated or injected. Yet though Suboxone reduces the risk of adult misuse this way, it still endangers children who mistakenly take the pills.

To address this problem, Indivior introduced a new drug called Suboxone Film. As the name suggests, Suboxone Film is the same drug. But rather than being packaged as pills, it’s a strip that dissolves under the tongue. Indivior hoped that children would be less likely to take individually wrapped film by accident than to swallow pills (thinking they were food or candy).

This case began with Indivior’s efforts to sell Suboxone Film in Massachusetts.

Doing that depended on MassHealth, Massachusetts’s state-run Medicaid program. If MassHealth put a drug on its “preferred” drug list, more doctors would prescribe it—or so the theory went. And getting Suboxone Film on that list depended on persuading MassHealth that Film was better than its competition. Indivior’s plan was straightforward:

1

Indivior is a successor entity to Reckitt Benckiser Pharmaceuticals.

persuade MassHealth to cover more Suboxone Film prescriptions by giving MassHealth data showing that Film had better pediatric-exposure figures than its predecessors.

But in trying to do that, Indivior ran into a problem. The data didn’t show what Indivior wanted it to show. Rather than proving that Suboxone Film posed the lowest risk to children, the data suggested that Subutex—the oldest drug in Indivior’s stable—posed the lowest risk to children.

So Indivior doctored the numbers. It added the child-exposure rates for both pills—

Suboxone and Subutex—and compared the sum to Suboxone Film’s child-exposure rate. This incorrectly suggested that Film was less risky than either older drug. Then Indivior employees packaged the data into a chart and sent it to MassHealth. Eventually, MassHealth placed Suboxone Film on its “preferred” list, making it available to more patients.

B. Baxter Pleads Guilty as a Responsible Corporate Officer In 2020, federal prosecutors charged Baxter with misdemeanor drug misbranding in violation of 21 U.S.C. § 331(a). That statute makes it a federal crime to cause “[t]he introduction or delivery for introduction into interstate commerce of any . . . drug . . . that is adulterated or misbranded.” Id. And a drug counts as misbranded if its manufacturer distributes “exhibits, literature, . . . or visual matter,” 21 C.F.R. § 202.1(l)(2), that are “false or misleading in any particular,” 21 U.S.C. § 352(a)(1).

Baxter faced liability under that statute even though he didn’t personally prepare or send the misleading data. Under what we have called the “responsible corporate officer doctrine,” United States v. Ming Hong, 242 F.3d 528, 531 (4th Cir. 2001), he was liable

for what his company did just because of his supervisory role—even if he didn’t know about the misbranding or do it himself. United States v. Park, 421 U.S. 658, 672–73 (1975). 2 Baxter pleaded guilty. As part of his plea agreement, he admitted that he “caused the introduction and delivery for introduction into interstate commerce of Suboxone Film.” J.A. 346. He likewise admitted that Suboxone Film was misbranded and that the misbranding caused MassHealth to cover it.

C. The Secretary Excludes Baxter from Federal Healthcare Programs After Baxter’s conviction, the Secretary of Health and Human Services told Baxter that he was “required . . . to exclude [Baxter] from participation in all Federal health care programs.” J.A. 527. Exclusion means that “no payment may be made by any Federal health care program,” like Medicaid, “for any items or services” that Baxter “furnishes, orders, or prescribes.” Id. (cleaned up). In the Secretary’s view, that exclusion arose from 42 U.S.C. § 1320a-7(a), which provides that “[t]he Secretary [of HHS] shall exclude . . . from participation in any Federal health care program . . . any individual or entity that has been convicted of a criminal offense related to the delivery of an item or service under [Medicare] or under any State health care program.” Baxter tried and failed to persuade the Secretary otherwise. His agency appeals failed as well.

2

This doctrine has sparked controversy in some quarters. But Baxter rightly does not challenge it here in this collateral proceeding.

D. Baxter Sues

Free access — add to your briefcase to read the full text and ask questions with AI

Timothy Baxter v. Robert Kennedy, Jr., 136 F.4th 70 (4th Cir. 2025).

136 F.4th 70 (Timothy Baxter v. Robert Kennedy, Jr.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Jordan v. De George
341 U.S. 223 (Supreme Court, 1951)
Morissette v. United States
342 U.S. 246 (Supreme Court, 1952)
Morrissey v. Brewer
408 U.S. 471 (Supreme Court, 1972)
United States v. Park
421 U.S. 658 (Supreme Court, 1975)
Cleveland Board of Education v. Loudermill
470 U.S. 532 (Supreme Court, 1985)
Taylor v. United States
495 U.S. 575 (Supreme Court, 1990)
Morales v. Trans World Airlines, Inc.
504 U.S. 374 (Supreme Court, 1992)
Almendarez-Torres v. United States
523 U.S. 224 (Supreme Court, 1998)
Leocal v. Ashcroft
543 U.S. 1 (Supreme Court, 2004)
Jama v. Immigration and Customs Enforcement
543 U.S. 335 (Supreme Court, 2005)
Shepard v. United States
544 U.S. 13 (Supreme Court, 2005)
Gonzales v. Duenas-Alvarez
549 U.S. 183 (Supreme Court, 2007)
Begay v. United States
553 U.S. 137 (Supreme Court, 2008)
Nijhawan v. Holder
557 U.S. 29 (Supreme Court, 2009)
United States v. Hayes
555 U.S. 415 (Supreme Court, 2009)
United States v. Meade
175 F.3d 215 (First Circuit, 1999)
Ram v. Heckler
792 F.2d 444 (Fourth Circuit, 1986)
Ricardo Prudencio v. Eric Holder, Jr.
669 F.3d 472 (Fourth Circuit, 2012)
Kawashima v. Holder
132 S. Ct. 1166 (Supreme Court, 2012)